Overview

Keyhole Limpet Hemocyanin in Chronic Hepatitis C

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
0
Participant gender:
All
Summary
In this study the investigators examine the safety and efficacy of Keyhole-limpet-hemocyanin in patients with chronic hepatitis c infection and liver cirrhosis. The investigators hypothesize that administration of keyhole-limpet-hemocyanin reduces the viral load in patients infected with hepatitis c.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical University of Graz
Treatments:
Keyhole-limpet hemocyanin
Criteria
Inclusion Criteria:

- Chronic Hepatitis C infection

- no previous therapy

- at least one contraindication to interferon therapy

- liver cirrhosis

- age between 18-80 y

- women of not childbearing age

Exclusion Criteria:

- Hypersensitivity against keyhole-limpet hemocyanin

- previous treatment against hepatitis c

- autoimmune disorders

- immunosuppression

- hepatocellular carcinoma or other malignancies

- coinfection with hepatitis b or HIV

- pregnancy

- cardiovascular event during the last 6 months (stroke or MCI)

- uncontrolled diabetes

- renal insufficiency (GFR < 50 ml/min) or chronic hemodialysis